|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell
- Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY . . . - Amgen
IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages . . .
Tarlatamab, marketed as Imdelltra, is a bispecific T-cell engager (BiTE®) antibody that harnesses the body’s immune system to fight small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine tumors
- Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells
- DRUG NAME: Tarlatamab - bccancer. bc. ca
Tarlatamab is a bispecific T-cell engager that simultaneously binds to delta-like ligand 3 (DLL3) on tumour cells and CD3 receptors on T cells
- Practical management of adverse events in patients receiving tarlatamab . . .
Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer This review summarizes the safety profile of tarlatamab and outlines the strategies used for the management of common adverse events encountered during the DeLLphi‐301 trial INTRODUCTION
- Tarlatamab for Patients with Previously Treated Small-Cell . . . - PubMed
Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer
|
|
|